NasdaqGS:VRTXBiotechs
The Bull Case For Vertex Pharmaceuticals (VRTX) Could Change Following Major CFTR Therapy Label Expansion Approval
In early April 2026, Vertex Pharmaceuticals reported that the U.S. FDA approved expanded use of its cystic fibrosis therapies ALYFTREK and TRIKAFTA, making CFTR modulator treatment available to roughly 95% of people with cystic fibrosis in the U.S., including about 800 individuals newly eligible for a therapy that targets the disease’s underlying cause.
This broad label expansion deepens Vertex’s role in cystic fibrosis care and underscores the importance of its existing franchise even as...